The COVID-19 booster, which targets both the original virus that causes COVID-19 and the omicron BA.4 and BA.5 variants, is now available for children aged 5 to 11.
The boosters from Pfizer-BioNTech and Moderna were approved by the Food and Drug Administration on Wednesday morning. The Centers for Disease Control and Prevention's approval is anticipated to come shortly after.
The immunizations must to be readily accessible at neighborhood pharmacies and pediatricians' offices.
Start your day more wisely. Each morning, receive all the news you require in your inbox.
Children are less prone than adults to get COVID-19 infections, become really unwell, and pass away.
That risk is not zero, though. Pediatricians strongly advise that nearly all children receive the two-dose primary series of the COVID-19 vaccine as well as a booster because the vaccine has been found to be incredibly safe.
According to Dr. Peter Marks, director of the FDA's vaccination division, "There is the possibility for increased risk of exposure to the virus that causes COVID-19 as children have returned to school in person and people are continuing pre-pandemic habits and activities." "When children are eligible, we recommend parents to think about primary immunization and to follow up with an updated booster dose."
Before the holidays and an anticipated increase in cases during the winter, Dr. Ashish Jha, the White House COVID-19 coordinator, has recommended everyone to obtain a bivalent booster vaccine by October 31.
Vaccines take roughly two weeks to fully take action after an injection.
Jha urged attendees of a White House briefing on Tuesday, "Don't wait." "Get your COVID shot and updated flu vaccine today. Americans could save hundreds of lives every day this winter if we did that."
Adults are advised to postpone receiving a booster three months after contracting an infection. According to the FDA, children must wait at least two months following a prior illness or COVID-19 vaccination before receiving the booster.
The omicron version of the virus first surfaced around Thanksgiving 2021, and while the first two vaccine doses were quite effective against severe sickness early in the pandemic, research revealed a third injection was required to provide substantial protection.
It is acceptable, according to authorities, to have a COVID-19 booster at the same time as an annual flu vaccination.
Although a prior COVID-19 infection is thought to be protective against re-infection, this protection isn't perfect and wears off with time, especially in the face of novel variations, such with vaccinations.
Because it targets both the original virus and the variations that have been prevalent since the beginning of the summer, the new dose is referred as as a "bivalent" vaccine.Currently, BA.4 and BA.5 make up around 80% of the variants seen in the United States, a percentage that has decreased over the past several weeks. After BA.5, BA.4.6 is currently the second most popular form, while BA.7 is also becoming more popular. It's unclear how those more recent mutations may affect vaccinations and therapies.
Following final quality control checks, Pfizer and its partner BioNTech announced they are ready to dispatch the boosters right away.
Pfizer's spokesperson Steve Danehy said in a statement that the company has the potential to send up to 6 million pediatric doses in the first seven calendar days "without any impact on distribution output of the dosages for adults 12 years and older."
A modified COVID-19 booster shot has been approved by the FDA for use in the fall.
The new Pfizer-BioNTech booster is the same one that's offered for older kids and adults; it only comes in a lesser amount—10 micrograms as opposed to the adult dose of 30 micrograms.There is no discernible difference between the Pfizer-BioNTech and Moderna boosters in terms of efficacy or adverse effects, or when the two vaccinations are combined. Children as young as 5 can receive the Pfizer-BioNTech vaccination, however children as young as 6 can only receive the Moderna vaccine.
The booster's clinical trials in younger children have not yet been finished by the businesses. The FDA determined that the switch to a bivalent vaccine is not anticipated to have an impact or risk profile that differs from the prior injections. Without human testing, flu vaccines are similarly modified each year to address circulating variations.
The FDA and CDC both came to the conclusion that the new boosters did not differ sufficiently from earlier doses to warrant consultation with their expert advisory panels.
Despite Novavax, whose vaccine is based on a different technology, asking for approval to administer their vaccination as a primary series in that age range, they are the only two COVID-19 vaccines now offered for children aged 5 to 12 in the United States.
It is unclear if or when the booster will be made accessible to even younger kids. Even though the Modern'a vaccine is only approved for two shots for children as young as six months old, it is already advised that they receive three doses as their initial course of treatment.
Adrianna Rodriguez has contributed.
[zombify_post]
0 Comments